BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will soon publish a comprehensive market analysis and a forecast though 2022 for both the hepatitis C virus (HCV) drug market and the hospital-treated bacterial infections drug market.
Key findings from the upcoming Pharmacor advisory service entitled Hepatitis C Virus reveal that Gilead's Sovaldi—the first direct acting antiviral (DAA) approved for the treatment of HCV as part of an IFN-free regimen—represents a safe, convenient (all-oral), and highly efficacious option for genotype-1, -2 and -3 patients, particularly those who are unable or unwilling to undergo treatment with IFN-based regimens. Sovaldi, as well as Janssen/Medivir's Olysio/Sovriad, were both recently approved by the U.S. Food and Drug Administration for the treatment of both treatment-naive and treatment-experienced HCV patients.
The findings also reveal that the HCV pipeline is dynamic and competitive, owing to the large commercial potential that is well recognized by pharmaceutical developers. Agents in late-stage development—such as protease inhibitors (AbbVie's ritonavir-boosted ABT-450, Boehringer-Ingelheim's faldaprevir, Merck's MK-5172), polymerase inhibitors (AbbVie's ABT-333, Bristol-Myers Squibb's BMS-791325, Boehringer-Ingelheim's deleobuvir) and NS5A inhibitors (Bristol-Myers Squibb's daclatasvir, Gilead's ledipasvir and GS-5816, AbbVie's ABT-267 and Merck's MK-8742), among others—are expected to drive dramatic growth of the HCV market through 2022. These DAAs are being evaluated in all-oral, IFN-free regimens consisting of 2-3 DAAs in combinations with and without ribavirin.
Key findings from the upcoming Pharmacor advisory service entitled Hospital-Treated Infections reveal that two beta-lactam/beta-lactamase inhibitors—Cubist's CXA-201 and Forest/AstraZeneca's CAZ-AVI—are poised for commercial success, owing to their activity against extended-spectrum beta-lactamase (ESBL)-producing gram-negative pathogens. Both therapies are expected to gain traction as infections due to ESBL producers have become more prevalent across all major markets, especially among urinary tract infections (UTIs), complicated intra-abdominal infections (cIAIs) and nosocomial pneumonia.
However, because of avibactam's expanded activity against Klebsiella pneumoniae carbapenemases (KPCs) and class C ESBLs, which the currently marketed beta-lactamase inhibitor tazobactam lacks, Decision Resources expects greater uptake of CAZ-AVI in indications where these drug-resistance mechanisms are prevalent, specifically UTIs and cIAIs. Conversely, given CXA-201's activity against a range of drug-resistant Pseudomonas aeruginosa isolates—including those resistant to the carbapenem imipenem/cilastatin (Merck's Primaxin/Tienam, generics)—this agent is expected to be reserved for serious gram-negative infections due to this pathogen.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources